RxDoctor Payments Data

Andrew Shors, MD

Dermatology · Kalispell, MTNPI 1669552659

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.6% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 24.8% of the total. 2025 is the largest year on record at $440, 2.4 times the $184 reported in 2019. That places this record below the midpoint for dermatology clinicians in MT, where the typical reported total is $1,595.

$1,491in general payments, 2019–2025

Across 55 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370
  • Johnson & Johnson$361
  • Lilly USA, LLC$337
  • Pfizer$81
  • Boehringer Ingelheim$60
  • Incyte Corporation$56
  • plus $226 from 6 others
$15,148in research payments, 2019–2025

Across 3 payments — averaging $5049.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$15K

What the payments were for

  • Food & beverage$1,39694%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,491 in reported general payments places this provider in the 45th percentile of 46 dermatology providers in Montana.

See all dermatology providers in Montana

Medicare billing

Part B allowed, 2024
$929,879
Medicare patients
1,617
Services billed
10,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate107$3,859
Metronidazole52$2,842
Triamcinolone Acetonide172$1,691
Doxycycline Hyclate49$1,458
Ketoconazole71$1,344
Cephalexin53$709
Mupirocin69$565
Hydrocortisone74$496
Clindamycin Phosphate13$332
Doxycycline Monohydrate11$327

Paid to pharmacies, not to this prescriber.

Other dermatology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →